[go: up one dir, main page]

ZA946324B - Antipsychotic method - Google Patents

Antipsychotic method

Info

Publication number
ZA946324B
ZA946324B ZA946324A ZA946324A ZA946324B ZA 946324 B ZA946324 B ZA 946324B ZA 946324 A ZA946324 A ZA 946324A ZA 946324 A ZA946324 A ZA 946324A ZA 946324 B ZA946324 B ZA 946324B
Authority
ZA
South Africa
Prior art keywords
mammal
antipsychotic method
antipsychotic
schizophrenia
sulphur
Prior art date
Application number
ZA946324A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA946324B publication Critical patent/ZA946324B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA946324A 1993-08-19 1994-08-19 Antipsychotic method ZA946324B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19

Publications (1)

Publication Number Publication Date
ZA946324B true ZA946324B (en) 1996-02-19

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA946324A ZA946324B (en) 1993-08-19 1994-08-19 Antipsychotic method

Country Status (23)

Country Link
EP (1) EP0734259B1 (xx)
JP (1) JP3126736B2 (xx)
KR (1) KR100360575B1 (xx)
CN (1) CN1087936C (xx)
AT (1) ATE218864T1 (xx)
AU (1) AU701292B2 (xx)
CA (1) CA2169839C (xx)
CZ (1) CZ285030B6 (xx)
DE (1) DE69430816T2 (xx)
DK (1) DK0734259T3 (xx)
ES (1) ES2177581T3 (xx)
FI (2) FI960747A7 (xx)
HU (1) HU221729B1 (xx)
IL (1) IL110708A (xx)
NO (1) NO312706B1 (xx)
NZ (2) NZ336597A (xx)
PT (1) PT734259E (xx)
RU (1) RU2191580C2 (xx)
SG (1) SG55071A1 (xx)
TW (1) TW442284B (xx)
UA (1) UA63876C2 (xx)
WO (1) WO1995005174A1 (xx)
ZA (1) ZA946324B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
IL115811A0 (en) * 1994-10-31 1996-01-19 Lilly Co Eli Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
ES2171838T3 (es) * 1996-08-01 2002-09-16 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para el tratamiento del trastorno bipolar.
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
ES2227836T3 (es) 1997-05-29 2005-04-01 H. Lundbeck A/S Tratamiento de esquizofrenia y psicosis.
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
CN119161338B (zh) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
AU7490294A (en) 1995-03-14
DE69430816D1 (de) 2002-07-18
ES2177581T3 (es) 2002-12-16
CZ42696A3 (en) 1996-11-13
NO960619L (no) 1996-04-18
HUT75111A (en) 1997-04-28
IL110708A0 (en) 1994-11-11
CA2169839A1 (en) 1995-02-23
TW442284B (en) 2001-06-23
KR100360575B1 (ko) 2003-03-10
JP3126736B2 (ja) 2001-01-22
SG55071A1 (en) 1998-12-21
ATE218864T1 (de) 2002-06-15
UA63876C2 (en) 2004-02-16
FI20050461L (fi) 2005-04-29
NO312706B1 (no) 2002-06-24
AU701292B2 (en) 1999-01-21
WO1995005174A1 (en) 1995-02-23
DK0734259T3 (da) 2002-09-30
NO960619D0 (no) 1996-02-16
IL110708A (en) 1998-12-06
FI960747L (fi) 1996-04-17
HU221729B1 (hu) 2002-12-28
DE69430816T2 (de) 2002-12-19
JPH09501658A (ja) 1997-02-18
NZ271311A (en) 1999-09-29
CN1087936C (zh) 2002-07-24
PT734259E (pt) 2002-11-29
EP0734259B1 (en) 2002-06-12
FI20050461A7 (fi) 2005-04-29
HU9600364D0 (en) 1996-04-29
CZ285030B6 (cs) 1999-05-12
RU2191580C2 (ru) 2002-10-27
KR960703592A (ko) 1996-08-31
FI960747A7 (fi) 1996-04-17
EP0734259A1 (en) 1996-10-02
CA2169839C (en) 2002-06-11
CN1133008A (zh) 1996-10-09
FI960747A0 (fi) 1996-02-19
NZ336597A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
SG55071A1 (en) Antipsychotic method
EP0604641A4 (en) COMPOSITION CONTAINING AMINO DERIVATIVES OR RELATED TO BENZOIC ACID AMINES AND USES THEREOF, INCLUDING IN THE TREATMENT OF INFLAMMATORY DISEASES.
EP0613883A4 (en) HYDROXAMIC ACID DERIVATIVE.
ZA917744B (en) Fused ring analogs of nitrogen containing nonaromatic heterocycles.
HUT73854A (en) Antipsychotic pharmaceutical compositions containing azabicyclo-thiadiazolo- or azabicyclo-oxadiazolo-derivatives
TW232013B (xx)
MX9803901A (es) Compuestos de di-terbutilfenol que contienen azufre utiles como agentes anti-inflamatorios.
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
ZA908460B (en) Benzocycloalkylaminopyridinamines and related compounds,a process and intermediates for their preparation and their use as medicaments
GR852867B (xx)
ZA9410287B (en) N-oxides of 4-arylpiperazines and 4-arylpiperidines
NO20003481L (no) FremgangsmÕte for behandling av COPD
AU653311B2 (en) Benzo(B)thiophen-3-yl-piperazines, as anti-psychotic agents
AU4610689A (en) Pyridine-3-peroxycarboxylic acid monopersulfate
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders